Alirinetide
Peptideexperimental
Clinical trial activity
2 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2011 (NCT01221246)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gm602
- gm608
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01850381 | Phase 2 | Jun 1, 2013 | Columbia University, Genervon Biopharmaceuticals, LLC |
| NCT01221246 | Phase 2 | Feb 1, 2011 | Columbia University, Genervon Biopharmaceuticals, LLC, Hoag Memorial Hospital Presbyterian, Huntington Memorial Hospital, Sarasota Memorial Hospital, University of California, Los Angeles, University of California, San Francisco, University of Erlangen-Nuremberg, University of Louisville, University of Southern California |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Columbia University | Academic/Hospital | 2 | 0 | 1 | 2011 |
| Genervon Biopharmaceuticals, LLC | For profit | 2 | 2 | 1 | 2011 |
| Hoag Memorial Hospital Presbyterian | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Huntington Memorial Hospital | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Sarasota Memorial Hospital | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Erlangen-Nuremberg | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Louisville | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Southern California | Academic/Hospital | 1 | 0 | 1 | 2011 |
10 organizations
Page 1 / 1